HomeContact: Chris.Gallagher@bartsandthelondon.nhs.uk
Professional interests
Dr Chris Gallagher is a consultant medical oncologist and the Cancer Services Clinical Director at St Bartholomew's Hospital Barts and the London NHS Trust and Honorary Senior Lecturer in the Barts and the London School of Medicine and Dentistry. He trained in Oncology at St Bartholomew's and the Royal Marsden Hospitals and in research at the ICRF Lincoln's Inn Fields. He specializes in Gynaecological and Breast cancers and participates in national and international collaborative trials in ovarian and breast cancer. He is a member of the NCRI Gynaecological clinical studies group and the CRUK Clinical Trials Awards Advisory Committee. He has lead the development of cancer services for the Barts and the London NHS Trust within the North East London Network with the creation of new consultant posts, directorate clinical governance, clinical IT systems, and planning of the new hospital Comprehensive Cancer Centre. He has lead the development at BLT of oncology clinical education and training for Foundation year and Speciality trainees and promotes the development of oncology training through membership of the RCP subspecialty committee, the Association of Cancer Physicians, and the E-learning board of the Joint Council for Clinical Oncology.
Recent Publications:
- Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. British J Cancer 2008;98(2):289-93.
- Gallagher CJ, Reznek RH, Husband JES. Radiological investigation of carcinoma of unknown primary site. In: Husband JES, Reznek RH editors. Imaging in Oncology. Oxford. Isis Medical Media, 2004. p1169-79. Reissued 2008
- Gallagher CJ, Lister TA. Oncology: Haematological and Solid tumours in Medicine. In Kumar P, Clark, M editors. Clinical Medicine. Harcourt Health Sciences, 2004. p473-510. Reissued 2008
- Sahdev A, Hughes JH, Barwick T, Rockall AG, Gallagher CJ, Reznek RH. Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol 2007;48(9):1038-44.
- Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH, Yip D, Lofts F, Gallagher C, Thomas H, Harper PG. Gemcitabine and Oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, and advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First study. Gynecol Oncol 2006;103:439-45.
- Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RCF Mansi JL. A phase III randomised trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Group study. J Clinical Oncology 2005;23:2988-95.
- Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C. J, Bengala C, Tres A, Welch R, Lawton P, Rubens R, Woods E, Haviland J, Vigushin D, Kanfer E, Bliss JM, on behalf of the International collaborative Cancer Group (ICCG). High dose chemotherapy and autologous stem cell transplanation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Annals of Oncology 2005;16:726-34.
- Barlow C, Nystrom M, Oesterling C, Fennel D, Ismay J, Gallagher C. Dose Intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer 2004;90:1318-22.
- Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, Olson K, Gibbens I, Gore ME. Attitudes to chemotherapy in patients with ovarian cancer. Gynecologic Oncology 2004;94:427-35.
